Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of January 19, 2026 [1] Core Insights - 2025 marked a significant year for Chinese innovative drugs going global, with a total transaction amount of $135.655 billion, including $7 billion in upfront payments and 157 deals, setting historical highs. The trend continues into 2026, with notable licensing agreements from companies like Yilian Biotech and Rongchang Biotech, indicating strong global competitiveness for Chinese innovative drugs [2] - Major companies are increasingly investing in the small nucleic acid field, with significant acquisitions and clinical approvals. For instance, China National Pharmaceutical Group acquired Hangzhou Hejiya Biopharmaceutical for 1.2 billion RMB, while international firms like Novartis and GSK are also advancing in this area [3] - The GLP-1 market is expected to grow despite new pricing systems, with ongoing collaborations and new product launches anticipated in 2026. The market for GLP-1 drugs is projected to remain robust due to the large patient population for weight loss and diabetes [4] - The oral autoimmune drug market is gaining attention, with promising results from Takeda's new TYK2 inhibitor for psoriasis. Other domestic companies are also advancing in this space, exploring new targets for oral small molecules [5] - The brain-computer interface sector is poised for industrialization, with companies like Neuralink set to produce devices in 2026. Domestic advancements and regulatory support are enhancing the potential for this technology in medical applications [6] - The ZAP-X radiation therapy device is expected to capture a significant market share in China, with rapid growth projected in non-invasive tumor radiation treatment, driven by increasing clinical recognition and adoption [8] Summary by Sections Industry Trends - The pharmaceutical sector is witnessing a resurgence in interest towards innovative drugs, with a notable increase in the innovative drug index by 8.97% since early January 2026, outperforming the CSI 300 index by 6.77 percentage points [2] Company Recommendations - Recommended companies include: - **Yuekang Pharmaceutical** and **Sunshine Nuohua** in the small nucleic acid space - **Yahong Pharmaceutical** and **Yifang Biotechnology** in the autoimmune sector - **Zhongsheng Pharmaceutical** in the GLP-1 market - **Baiyang Pharmaceutical** for ZAP-X radiation therapy - **Meihao Medical** for brain-computer interface technology [10] Market Opportunities - The non-invasive tumor radiation treatment market is projected to grow from 27.2 billion RMB in 2018 to 59.4 billion RMB by 2024, with a compound annual growth rate of 13.9% [8]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [2]. Core Insights - The report highlights the ongoing performance of the pharmaceutical sector, with a focus on the upcoming annual earnings forecasts and the potential for exceeding expectations. The sector has shown a return of 7.08% since the beginning of 2026, outperforming the CSI 300 index by 4.88% [8][12]. - Key catalysts in the industry include significant partnerships and acquisitions, such as AbbVie’s $6.5 billion upfront payment for RC148 and a $1 billion collaboration between Eli Lilly and NVIDIA to accelerate AI drug development [4][10]. - The report emphasizes the importance of innovative drug chains and the AI+ theme, suggesting that these areas will continue to attract investment and yield positive results [4][5]. Summary by Sections Industry Overview - The pharmaceutical sector's total market capitalization is approximately 74,744.70 billion yuan, with a circulating market value of 68,522.64 billion yuan [2]. - The report notes that the pharmaceutical sector is currently valued at 23.4 times PE based on 2026 earnings forecasts, which is a premium of 13.7% compared to the overall A-share market [15]. Market Dynamics - The report indicates that the pharmaceutical sector has experienced a mixed performance, with medical services up by 3.29% while other segments like medical devices and traditional Chinese medicine have seen declines [8][12]. - The report also mentions that the market is transitioning to a more rational and steady growth phase, moving away from the initial volatility seen at the start of the year [4]. Key Company Performances - Notable companies such as WuXi Biologics, Sangamo Therapeutics, and Tigermed have been highlighted for their strong performance, with WuXi Biologics showing a significant increase of 26.53% in January [24]. - The report suggests continued monitoring of companies involved in AI and small nucleic acid technologies, as they are expected to lead future growth in the sector [5][9]. Investment Recommendations - The report recommends focusing on companies that are well-positioned within the innovative drug chain and AI+ sectors, as these are anticipated to provide substantial returns [4][5]. - Specific stocks recommended include WuXi Biologics, Sangamo Therapeutics, and Tigermed, which have shown promising growth trajectories [24].

Group 1 - The Hong Kong Innovation Drug ETF (159570) has experienced a 2.5% decline for three consecutive days, with a trading volume exceeding 800 million yuan, and has attracted over 1 billion yuan in the last five days [1][3] - As of January 16, the latest scale of the Hong Kong Innovation Drug ETF (159570) has surpassed 26.2 billion yuan, leading its peers in the same category [1] - The majority of the weighted stocks in the ETF's index have shown negative performance, with notable declines including Kelun-Bio down over 5%, Innovent Biologics and Hansoh Pharmaceutical down over 4%, and others down over 3% [3][4] Group 2 - The 44th JPMorgan Healthcare Conference took place from January 12 to 15, featuring several Chinese innovative pharmaceutical companies, including WuXi AppTec and BeiGene, among others [5] - Huatai Securities noted that the JPM conference and the upcoming annual report cycle in February could serve as catalysts for the market, which is currently at a relative bottom, with expectations for new highs in the innovative drug sector [5] - Zhongtai Securities highlighted multiple catalysts in the pharmaceutical sector, including significant data disclosures from multinational corporations and various business development deals, indicating a positive outlook for the innovative drug industry [5][6] Group 3 - The 2026 JPMorgan Conference is expected to showcase Chinese innovative drugs as a global highlight, with over 20 Chinese pharmaceutical companies participating [7] - Companies like HengRui are projected to see a 25%+ growth in innovative drug revenue by 2026, with several key drugs and indications expected to be approved in the next two years [7] - Notable developments include RC148's licensing deal worth up to 5.6 billion USD between Rongchang Bio and AbbVie, and various clinical trial advancements from companies like Summit Therapeutics and Eifang Bio [8]

Core Viewpoint - Novo Nordisk has experienced a significant market rebound following the successful launch of its oral version of Wegovy in the U.S., which exceeded initial prescription expectations, leading to a notable increase in its stock price [4][6]. Group 1: Product Performance - The oral Wegovy achieved approximately 3,100 prescriptions in its first week post-launch, with some estimates suggesting up to 4,290 prescriptions, significantly outperforming Eli Lilly's Zepbound, which had 1,300 to 1,900 prescriptions in its first week [4]. - Clinical data from the Phase 3 OASIS 4 trial indicated that patients on a daily 25 mg oral dose of Wegovy lost an average of 13.6% of their body weight over 64 weeks, with adherence leading to a weight loss of up to 16.6%, comparable to the injectable version [6]. Group 2: Market Strategy - Novo Nordisk adopted an aggressive pricing strategy for oral Wegovy, with a starting monthly price of $149, significantly lower than the injectable version priced at $349, signaling a shift from high pricing to broader market coverage [7]. - The company has partnered with the Trump administration to offer oral Wegovy at discounted prices through the upcoming government-operated platform TrumpRx, enhancing drug accessibility [7]. - Novo Nordisk's distribution strategy includes partnerships with over 70,000 pharmacies and telehealth platforms like Ro and Weight Watchers, facilitating direct access to patients through a vertically integrated model [7]. Group 3: Competitive Landscape - Despite its current success, Novo Nordisk's advantage is not guaranteed, as Eli Lilly is advancing its oral small molecule GLP-1 drug, orforglipron, which may present new competition due to its lack of strict post-dosing dietary restrictions [10]. - Analysts project that oral Wegovy's long-term annual sales could reach approximately $3.3 billion, which, while only a fraction of the injectable version's potential, is seen as a critical strategic asset for Novo Nordisk in the obesity market [10].

Core Viewpoint - The article highlights the exceptional performance of Shengnuo Biopharmaceuticals, which is expected to achieve a net profit of 152 million to 190 million yuan in 2025, marking a year-on-year increase of 204.42% to 280.53% [6]. Group 1: Company Performance - Shengnuo Biopharmaceuticals' projected net profit for 2025 is significantly higher than market expectations, with a forecasted increase of 1.02 billion to 1.40 billion yuan compared to the previous year [6]. - In contrast, the company's performance in 2024 showed a mere 4.84% revenue growth to 456 million yuan, with a net profit decline of 28.88% to 50.02 million yuan due to pricing pressures and increased R&D investments [6]. - The surge in 2025 is attributed to the overseas demand for GLP-1 raw materials, particularly for drugs like semaglutide and tirzepatide, which has led to a 232.3% increase in raw material revenue [8]. Group 2: Industry Dynamics - The global market for GLP-1 drugs is expanding rapidly, with predictions that the annual demand for GLP-1 raw materials could reach 50 tons by 2030 [9]. - The expiration of key patents for semaglutide in 2026 is expected to trigger a surge in the development and approval of generic and modified drugs, further increasing demand for raw materials [9]. - Shengnuo Biopharmaceuticals is positioned competitively in the domestic market, with an expected total production capacity of approximately 1.25 tons of peptide raw materials by the end of 2025 [8]. Group 3: Future Outlook - The growth logic for GLP-1 raw materials is anticipated to continue, with a tight supply-demand balance expected to persist in the short term [9]. - The industry is entering a phase of capacity competition, with several companies accelerating production, which may lead to price competition and margin pressure [9]. - Shengnuo Biopharmaceuticals' success in 2025 is seen as a result of strategically capitalizing on the global demand for GLP-1 raw materials, rather than a mere short-term luck [9].

Group 1 - Novo Nordisk's stock surged by 8% on January 16, reaching a peak of $62.02, the highest level since September of the previous year, with a market capitalization of $273.5 billion [1] - The early prescription data for Novo Nordisk's newly launched oral GLP-1 medication for obesity shows promising results, with approximately 3,100 prescriptions in the first week [3] - Comparatively, Eli Lilly's injectable weight loss drug Zepbound garnered about 1,900 prescriptions in its first full week post-launch, indicating a strong start for Novo Nordisk's oral medication [3] Group 2 - Analysts caution that more data is needed to fully assess the early demand for the Wegovy oral medication [4] - The direct sales channel is expected to have significant potential for promoting the oral medication, and analysts are eager to see its complete performance [5] - The weight loss and diabetes medication market is experiencing rapid growth, with Eli Lilly holding a significant market share and preparing to launch its own oral obesity medication [6] Group 3 - The demand landscape may change in the coming months with the anticipated market entry of Eli Lilly's oral drug orforglipron [7] - Although Novo Nordisk currently has a first-mover advantage, its peptide-based medication has dietary restrictions that may affect user acceptance [7] - In contrast, Eli Lilly's drug is a small molecule compound, which does not have the same dietary limitations [8]

Core Viewpoint - The recent exclusive licensing agreement between Rongchang Biologics and AbbVie for the dual-specific antibody drug RC148, targeting PD-1/VEGF, highlights the competitive landscape in the oncology drug market, with significant financial implications for both companies [1][5]. Group 1: Licensing Agreement Details - Rongchang Biologics has entered into an exclusive licensing agreement with AbbVie for RC148, which is currently in Phase II clinical trials [1]. - The deal includes an upfront payment of $650 million and potential milestone payments up to $4.95 billion, along with tiered royalties on net sales, bringing the total potential value of the agreement to $5.5 billion [1]. - Following the announcement, Rongchang Biologics' stock surged, with a 20% increase in A-shares and a 7.87% increase in Hong Kong shares [1]. Group 2: Market Context and Comparisons - The PD-1/VEGF target has seen multiple drugs developed, with over five similar drugs already in the market, leading to skepticism about the market share for later entrants [1][4]. - Other Chinese biotech firms have also engaged in significant licensing deals for PD-1/VEGF drugs, with notable transactions including a $500 million upfront payment from Summit to Kanyos Biologics and a $1.25 billion upfront payment from a partnership involving 3SBio and Pfizer [4]. - Despite being ranked lower in the market, Rongchang Biologics' deal value is comparable to that of Kanyos Biologics, raising questions about the valuation of later-stage products [5]. Group 3: Future Prospects and Trends - There is an expectation for continued licensing transactions in the PD-1/VEGF space, driven by efficacy, different indications, and combination therapies [8]. - Companies with PD-1/VEGF candidates that have not yet been licensed are actively seeking opportunities, with the potential for significant deals depending on product data and market conditions [8]. - Major multinational pharmaceutical companies, including Eli Lilly, Novartis, and AstraZeneca, have not yet announced new PD-1/VEGF acquisitions, indicating potential future market activity [9].

Investment Rating - The report indicates a positive outlook for the AI+Pharma and AI+Healthcare sectors, suggesting a shift towards data and algorithm-driven drug development and clinical applications [3][6]. Core Insights - The collaboration between NVIDIA and Eli Lilly to establish the first AI+Pharma joint innovation lab signifies a major step in integrating AI into drug R&D, with a planned investment of up to 1 billion USD over five years [3][6]. - Tempus AI's preliminary revenue for 2025 reached approximately 1.27 billion USD, reflecting an 83% year-over-year growth, validating the commercial viability of AI in clinical testing and medical data [3][6]. - The industry is currently experiencing a phase characterized by technological breakthroughs, active funding, and accelerated application of AI in pharmaceuticals and healthcare [3][6]. Summary by Sections AI+Pharma - The establishment of the AI+Pharma lab aims to address key challenges in drug development, combining expertise from both NVIDIA and Eli Lilly [3][6]. - The partnership is expected to elevate AI's role from a mere tool to a core productivity driver in drug R&D, transitioning the industry from experience-driven to data-driven methodologies [3][6]. AI+Healthcare - Tempus AI reported a diagnostic revenue of approximately 955 million USD, up 111% year-over-year, driven by significant growth in oncology and genetic testing [3][6]. - The data and application segment generated about 316 million USD, marking a 31% increase, with data licensing (Insights) growing by 38% [3][6]. Industry Trends - The report highlights a favorable environment for AI in pharmaceuticals, supported by technological advancements, policy backing, and a vibrant investment landscape [3][6]. - The launch of OpenAI's ChatGPT Health and the significant user engagement indicate a growing interest and application of AI technologies in healthcare [3][6]. - Relevant investment targets in AI drug discovery and healthcare applications include companies like XtalPi, Insilico Medicine, and Meinian Onehealth [3][6].

Fixed Income Research - The report highlights four key points regarding the EVE indicator for major banks, focusing on the impact of extended bond durations, deposit replacement, Tier 1 capital replenishment, and changes in the behavior of large banks in primary and secondary markets [2][3][4][5] - It emphasizes that the adjustment of the EVE indicator is more about risk mitigation rather than a significant increase in active long-term bond purchases by banks, suggesting that long-term supply pressures may limit the downward space for long-term interest rates [2][5] Metal New Materials Research: China Uranium Industry - China Uranium Industry derives over 90% of its revenue from natural uranium business and is the exclusive supplier of natural uranium products for its controlling shareholder, China National Nuclear Corporation (CNNC) [6][7] - The company is expected to see significant growth due to its role in national uranium supply and expansion in domestic capacity and overseas resource layout, with projected revenues of CNY 172.79 billion in 2024 and a net profit of CNY 14.58 billion [6][38] - The global uranium market is experiencing a supply-demand gap, with increasing demand driven by nuclear energy development, which is expected to benefit the company in the long term [8][40] Company Overview: China Uranium Industry - The company is the sole supplier of natural uranium products within CNNC, controlling 69.94% of the company’s shares, and has signed long-term supply agreements with China Nuclear Power [7][39] - It holds extensive domestic and international exploration and mining rights, with core uranium resources located in strategic areas such as Xinjiang and Namibia [7][39] - The report projects a net profit growth of CNY 17.62 billion, CNY 33.09 billion, and CNY 44.28 billion for the years 2025 to 2027, respectively, with corresponding EPS of CNY 0.85, CNY 1.60, and CNY 2.14 [6][38] Investment Recommendations - The report assigns a target price of CNY 80 for China Uranium Industry, based on a 50x PE valuation for 2026, and recommends an "Accumulate" rating [6][38] - The company is positioned to benefit from the long-term supply-demand gap in the uranium market, with a projected increase in global uranium demand expected to reach 150,500 tons by 2040 [8][40]

Group 1: Company Announcements - Rongbai Technology announced that its stock will be suspended for one day on January 16, 2026, due to receiving an inquiry letter from the Shanghai Stock Exchange regarding its daily operational contract with CATL, which requires further verification [1][7]. Group 2: Market Performance - On Wednesday, US stock indices closed higher, with the Dow Jones up 0.61%, Nasdaq up 0.21%, and S&P 500 up 0.27%. Notably, Nvidia rose over 2%, TSMC increased over 4%, while Google fell over 1% and Eli Lilly dropped over 4% [2][8]. - The Nasdaq Golden Dragon China Index declined by 0.60%, with significant drops in stocks such as Zhongjin Medical down 11.39%, Canaan down 6.25%, and Tencent Music down 4.95% [2][8]. Group 3: Macroeconomic Analysis - In November, China held $683 billion in US Treasury bonds, a decrease of $6 billion from October's $689 billion [3][10]. - The US saw a net capital inflow of $212 billion in November, a significant turnaround from a net outflow of $22.5 billion in October [3][11]. - Federal Reserve officials indicated a preference to maintain interest rates in the next meeting, with potential for a mild rate cut later in the year, although some expressed concerns that rate cuts could exacerbate inflation [3][11]. Group 4: Market Dynamics - In international precious metals, New York gold futures fell below $1,610 per ounce, down 0.28%, while spot gold rose slightly to above $1,620 per ounce, up 0.09% [4][12]. - Both spot silver and New York silver futures fell below $91 per ounce, with declines of 0.41% and 0.42%, respectively [5][12]. - US natural gas futures dropped over 3%, currently priced at $3.026 per million British thermal units [6][12].